An intellectually stimulating lifestyle is key to fighting Huntington's disease, finds study
An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...
BioSpace2d
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...
News Medical on MSN8d
Heart medication may slow the progression of Huntington's disease
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
MedPage Today on MSN9d
Beta-Blockers Tied to Delayed Huntington's Disease Progression
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease: A Promising Pathway to Accelerated Approval
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
The Irish News on MSN8d
New therapy for Huntington’s disease ‘may slow progression’
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused by a ...
BioPharma Dive2d
UniQure shares soar on chance of speedy approval for Huntington’s therapy
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
manilatimes3d
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 ...
Common heart drug may slow progression of Huntington's disease
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...
UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment
UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for ...